Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study

European Heart Journal

Volumn 38, Issue 24, 2017, Pages 1883-1890

  Ouwerkerk, W ^a   Voors, A A ^a,b   Anker, S D ^c   Cleland, J G ^d   Dickstein, K ^e,f   Filippatos, G ^g   Van Der Harst, P ^b   Hillege, H L ^b   Lang, C C ^h   Ter Maaten, J M ^b   Ng, L L ^i,m   Ponikowski, P ^j,n   Samani, N J ⁱ   Van Veldhuisen, D J ^b   Zannad, F ^k   Metra, M ^l   Zwinderman, A H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BERGEN   (Norway)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k CHU NANCY BRABOIS   (France)

^l UNIVERSITY OF BRESCIA   (Italy)

^m GLENFIELD HOSPITAL   (United Kingdom)

ⁿ MILITARY HOSPITAL   (Poland)

more..

Author keywords

ACE inhibitor; ARB; Beta blocker; Heart failure; Uptitration

Indexed keywords

ALKALINE PHOSPHATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

AGED; ARTICLE; BODY MASS; CLINICAL OUTCOME; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; EPIDEMIOLOGY; EUROPE; HEART FAILURE; KAPLAN MEIER METHOD; MORTALITY; MULTICENTER STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85021335865     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx026     Document Type: Article

References (53)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, Meer P van der. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 10.
2. The SOLVD Investigators. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. N Engl J Med 1991; 325: 293-302.
3. Garg R, Yusuf S, Bussmann WD, Sleight P, Uprichard A, Massie B, McGrath B, Nilsson B, Pitt B, Magnani B, Maskin C, Ambrosioni E, Rucinska E, Kleber FX, Jennings G, Tognoni G, Drexler H, Cleland JGF, Franciosa JA, Remes J, Swedberg K, Dickstein K, Maass L, Pfeffer M, Creager MA, Gordon M, Joy M, Sharpe N, Desche P, McGarry R, Collins R, Chrysant SG, Cicchetti V. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA J Am Med Assoc 1995; 273: 1450.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
5. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, Allaf D El, Vtovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol cr/xl randomized intervention trial in congestive heart failure (merit-hf). merit-hf study group. JAMA 2000; 283: 1295-1302.
6. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, Staiger C, Curtin EL, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
7. Poole-Wilson P a, Swedberg K, Cleland JG, Lenarda A Di, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (comet): randomised controlled trial. Lancet 2003; 362: 7-13.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
9. Flather MD, Shibata MC, Coats AJS, Veldhuisen DJ Van, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-225.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327: 685-691.
12. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A Comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
13. Packer M, Poole-Wilson P a., Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
14. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-2816.
15. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet Elsevier Ltd; 2009; 374: 1840-1848.
16. Cleland JG. Contemporary management of heart failure in clinical practice. Heart 2002; 88: Suppl 2 ii5-8.
17. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Gilst WH Van, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J. The EuroHeart Failure Survey programme - A survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474.
18. Kalra PR, Morley C, Barnes S, Menown I, Kassianos G, Padmanabhan S, Gupta S, Lang CC. Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. Int J Cardiol Elsevier Ireland Ltd; 2013; 167: 2695-2699.
19. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, Harst P van der, Hillege HL, Lang CC, Maaten JM ter, Ng L, Ponikowski P, Samani NJ, Veldhuisen DJ van, Zannad F, Zwinderman AH, Metra M. A systems biology study to tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016; 18: 716-726.
20. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, Veldhuisen DJ van, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, Caterina R De, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Document Reviewers. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. developed in collaboration with the heart. Eur Heart J 2008; 29: 2388-2442.
21. Lawless JF, Singhal K. Efficient Screening of Nonnormal Regression Models. Biometrics 1978; 34: 318.
22. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989; 8: 771-783.
23. Harrell, Jr FE. Regression Modeling Strategies. 2nd ed. Cham: Springer International Publishing; 2015.
24. Box GEP, Cox DR. An Analysis of Transformations Revisited, Rebutted. J Am Stat Assoc 1982; 77: 209.
25. Clark JE, Osborne JW, Gallagher P, Watson S. A simple method for optimising transformation of non-parametric data: an illustration by reference to cortisol assays. Hum Psychopharmacol Clin Exp 2016; 31: 259-267.
26. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw 2011; 45: 1-67.
27. Adelson JL. Reducing selection bias with propensity scores. Pract Assessment, Res Eval 2013; 18.
28. Holland PW. Statistics and causal inference. J Am Stat Assoc 1986; 81: 945-960.
29. Rubin DB. Causal inference using potential outcomes. J Am Stat Assoc 2005; 100: 322-331.
30. Robins JM, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994; 89: 846-866.
31. Zetterqvist J, Sjölander A. Doubly robust estimation with the R package drgee. Epidemiol Method 2015; 4.
32. Wal WM van der, Geskus RB. ipw: An R package for inverse probability weighting. J Stat Softw 2011; 43: 1-23.
33. Eilers PHC, Marx BD. Flexible smoothing with B-splines and penalties. Stat Sci 1996; 11: 89-121.
34. Willenheimer R, Veldhuisen DJ van, Silke B, Erdmann, Follath F, Krum H, Ponikowski P, Skene A, Ven L van de, Verkenne P, Lechat P. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized cardiac insufficiency bisoprolol study (cibis) iii. Circulation 2005; 112: 2426-2435.
35. Chatterjee S, Biondi-Zoccai G, Abbate A, D'Ascenzo F, Castagno D, Tassell B Van, Mukherjee D, Lichstein E. Benefits of b blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013; 346: f55.
36. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JCM. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-1309.
37. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
38. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L, Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with european society of cardiology guidelines evidence from 12, 440 patients of the esc heart failure long-term registry. Eur J Heart Fail 2013; 15: 1173-1184.
39. Düngen H-D, Apostolovic S, Inkrot S, Tahirovic E, Töpper A, Mehrhof F, Prettin C, Putnikovic B, Neskovic AN, Krotin M, Sakac D, Lainscak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R, CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBISELD trial. Eur J Heart Fail 2011; 13: 670-680.
40. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure-SIGNALHF (swedish intervention study-guidelines and NT-proBNP anaLysis in heart failure). Eur J Heart Fail 2010; 12: 1300-1308.
41. Brenyo A, Barsheshet A, Kutyifa V, Ruwald A-C, Rao M, Zareba W, Pouleur AC, Knappe D, Solomon SD, McNitt S, Huang DT, Moss AJ, Goldenberg I. Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction. Circ Hear Fail 2014; 7: 565-572.
42. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML. Inverse relationship of blood pressure levels to sudden cardiac mortality and benefit of the implantable cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2007; 49: 1427-1433.
43. Güder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT, Ertl G, Angermann CE, Stö rk S. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. circ hear fail 2009; 2: 563-571.
44. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Lenarda A Di, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol Elsevier Inc. ; 2011; 57: 1468-1476.
45. Güder G, Stö rk S, Gelbrich G, Brenner S, Deubner N, Morbach C, Wallenborn J, Berliner D, Ertl G, Angermann CE. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Eur J Heart Fail 2015; 17: 442-452.
46. Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000; 40: 11-30.
47. Alvarez A, Mukherjee D. Liver Abnormalities in Cardiac Diseases and Heart Failure. Int J Angiol 2011; 20: 135-142.
48. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
49. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481-489.
50. Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Rydén L. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med 2001; 161: 165-171.
51. Clement DL, Buyzere M De, Tomas M, Vanavermaete G. Long-term effects of clinical outcome with low and high dose in the captopril in heart insufficient patients study (CHIPS). Acta Cardiol 2000; 55: 1-7.
52. Nanas JN, Alexopoulos G, Anastasiou-Nana MI, Karidis K, Tirologos A, Zobolos S, Pirgakis V, Anthopoulos L, Sideris D, Stamatelopoulos SF, Moulopoulos SD. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. high enalapril dose study group. J Am Coll Cardiol 2000; 36: 2090-2095.
53. Dobre D, Veldhuisen DJ van, Mordenti G, Vintila M, Haaijer-Ruskamp FM, Coats AJS, Poole-Wilson PA, Flather MD. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure (SENIORS) trial. Am Heart J 2007; 154: 109-115.